A research team at the University of Pennsylvania (UPenn) has been working on preventing and treating genital herpes (HSV-2) for years and recently found success with an mRNA vaccine approach, even before the COVID-19 pandemic.
The goals of a HSV-2 vaccine are to keep the herpes virus dormant. Or if the virus escapes, prevent it from causing symptoms.
Professor Harvey M. Friedman demonstrated success in animal models in July 2020. This study found not only targeting entry molecules, but also targeting the HS-2 ability to evade the immune system.
Can mRNA Vaccines Defeat Herpes?
Many U.S. Colleges Will Mandate Vaccines on Campus Next Fall
Schools that are not requiring vaccinations are instead offering incentives to encourage students to get their shots
Vaccination Linked to Drop in COVID-19 Hospitalization in ≥65s
Vaccine effectiveness against COVID-19 hospitalization estimated at 94 percent for full vaccination with Pfizer-BioNTech, Moderna vaccines
COVID-19 Pill Could Be Available Later This Year: Pfizer CEO
If clinical trials are successful and the FDA approves the drug, it could be available across the United States later in 2021
Many Americans Have COVID-19 Vaccine Preferences
Most (36 percent) prefer Pfizer, followed by Moderna at 19 percent and Johnson & Johnson at 17 percent